Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
Publication Date: June 4, 2019
Key Points
Key Points
Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
Treatment
...Treatmen...
...linical circumstances ESAs may be offe...
...SAs should not be offered to patients with che...
...should not be offered to most patients with...
...may be offered to patients with lower risk...
...n patients with myeloma, non-Hodgkin’s ly...
...ffering an ESA, clinicians should conduct an...
...rt Panel considers epoetin beta and alf...
...he risk of thromboembolism, and clinicians shou...
...s recommended that starting and modifying...
...y be increased to the lowest concentration needed...
...As should be discontinued in patients who do...
...acement may be used to improve hemoglob...
...1. Suggested Baseline Investigatio...
...SA Adult DosingHaving trouble viewing tabl...
...e 3. Estimated Prices of ESAs and Supplem...